H.C. Wainwright targets Viking Therapeutics stock at USD 102.00: Viking starts Phase 3 trials

Published on 10/18/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viking starts oral VK2735 Phase 3 studies with 560 adults each. Viking Therapeutics stock faces 68-week trials after H.C. Wainwright set a USD 102.00 target.

Clinical pipeline and valuation

Viking began two oral VK2735 Phase 3 studies on October 14, 2026, each targeting 560 adults.
H.C. Wainwright reiterated a Buy rating with a USD 102.00 target on October 15, 2026.
Viking's next earnings date is October 28, 2026.

VKTX, US92686J1060, Illustration mit AI erstellt.

H.C. Wainwright reiterated a Buy rating and a USD 102.00 price target for Viking Therapeutics on October 15, 2026, one day after the company began two Phase 3 studies of oral VK2735. The clinical update gives the valuation view a concrete development milestone, but the trials will run for 68 weeks.

What does the trial mean for valuation?

According to The Globe and Mail, analyst Joseph Pantginis of H.C. Wainwright kept the Buy rating and USD 102.00 target in a report dated October 15, 2026. The target is an analyst assessment, not a clinical outcome. Viking's next evidence will have to come from the studies themselves.

Three dated steps in VK2735

On September 24, 2026, Viking priced an offering of 7,857,143 shares at USD 35.00 and issued USD 225.0 million of convertible notes, according to FinanzNachrichten. On October 6, 2026, the company started a maintenance-dosing study covering 195 adults with obesity, as stated in its Viking Therapeutics release. On October 14, 2026, Viking began SUNRISE-1 and SUNRISE-2, with 560 adults targeted in each study, according to Viking Therapeutics.

The next two dates matter

Investing.com lists October 28, 2026, as Viking's next earnings date. A separate maintenance study is expected to produce results in 2027, according to Boerse Express. Those dates separate near-term financial reporting from the longer clinical timetable.

Market value frames the risk

Viking's market capitalization was USD 3.2 billion on October 16, 2026. Its Nasdaq 52-week range was USD 24.94 to USD 43.15 on the same date, placing the valuation near the lower end of that recorded range. The business remains clinical-stage, so the USD 102.00 target rests on future development and regulatory execution rather than current product revenue.

The further course of trading is shown by the continuously updated real-time quote of Viking Therapeutics stock.